Thyrocare Technologies Reports Robust Q1FY27 Results: Consolidated Revenue Up 24%, PAT Surges 34%

Thyrocare Technologies Reports Robust Q1FY27 Results: Consolidated Revenue Up 24%, PAT Surges 34%​

Thyrocare Technologies Limited, a leading healthcare diagnostics company, reported strong results for the quarter ended June 30, 2026. The company announced consolidated revenue of ₹240.02 crore, marking a 24% year-on-year growth, while Profit After Tax (PAT) surged by 34% to ₹51.33 crore.

The robust performance highlights the continued momentum in the Pathology segment and the strategic expansion of Thyrocare’s service offerings.

Key Financial Performance Highlights​

Thyrocare delivered a significant leap in profitability during Q1FY27. Consolidated EBITDA grew by 34% year-on-year to ₹77.27 crore, underscoring the company's focus on operational efficiency and profitable growth.

The performance metrics for Thyrocare Technologies Limited across different quarters are detailed below:

Operational Strength and Specialty Expansion​

As India's largest diagnostic test volume processor, Thyrocare further solidified its leadership position in the market by processing 55.2 million tests in Q1FY27. This represents a strong 28% year-on-year growth in testing volume.

The Pathology business remains a core driver of growth, with franchise revenue increasing by 27% year-on-year and partnership revenue showing a 26% increase over the same period.

Thyrocare expanded its diagnostic capabilities into Specialty Diagnostics, marking a new frontier for the company. This expansion began with Allergy testing and has progressively incorporated Genomics services, focusing on scientific rigor and industry-leading turnaround times.

Commitment to Quality Excellence​

The focus on quality standards remained paramount during the quarter. Thyrocare achieved excellence in Six Sigma standards, reducing complaints per million tests to 3.1, which is a 24% decrease year-on-year. The company also reported an Average Turnaround Time (ATAT) of 3.37 hours from sample receipt, positioning it as India's first diagnostic chain to reach this benchmark.

Management Commentary​

Rahul Guha, MD and CEO of Thyrocare Technologies Ltd, commented on the results, stating that the strong performance was driven by continuous focus on operational efficiency, network expansion, and delivering value-driven diagnostics.

Guha further noted that the specialty portfolio was strengthened during the period with the addition of allergy testing and entry into genomics through the launch of NIPT (Non-Invasive Prenatal Testing). Thyrocare continues to scale its franchise and partner network while expanding its reach in underserved regions, reaffirming commitment to high-quality, affordable healthcare services across India.

THYROCARE Stock Price Movement​

Thyrocare Technologies Limited shares slipped by 2.41% today, closing at ₹545.25 as trading concluded post-market. The stock traded within a range of ₹541 to a high of ₹558.6 before settling, with 312,670 shares recorded in the final session.